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Context  
Adrenal crises (AC) cause morbidity and mortality in patients with Addison’s disease 
[primary adrenal insufficiency (PAI)]. Patient-initiated oral stress dosing, with parenteral 
hydrocortisone, is recommended to avert ACs. While these should be effective, the continued 
incidence of ACs remains largely unexplained.  
Methods 
Audit of all attendances between 2000 and 2017 by adult patients with treated PAI to one 
large regional referral centre in New South Wales, Australia. Measurements were those taken 
on arrival at hospital.  
Results  
There were 252 attendances by 56 patients with treated PAI during the study period. Women 
comprised 60.7% (n=34) of the patients. The mean age of attendees was 53.7 (19.6) years. 
Nearly half (45.2%, n=114) the patients had an infection. There were 61 (24.2%) ACs 
diagnosed by the treating clinician. Only 17.9% (n=45) of the hospital presentations followed 
any form of stress dosing. IM hydrocortisone was used before 7 (2.8%) attendances only. 
Among patients with a clinician diagnosed AC, only 32.8% (n=20) had used stress dosing 
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before presentation. Vomiting was reported by 47.6% (n=120) of the patients but only 33 
(27.5%) of these attempted stress dosing and 5 patients with vomiting used IM 
hydrocortisone. The number of prior presentations was a significant independent predictor of 
use of stress doses [1.05 (1.01,1.09)].  
Conclusion  
Dose escalation strategies are not used universally or correctly by unwell patients with PAI, 
many patients do not use IM or SC hydrocortisone injections. Previous hospital treatment 
increases the likelihood of stress dosing and offers the opportunity for reinforcement of 
prevention strategies. 
Key Words 
Addison’s disease; Hydrocortisone; Adrenal Insufficiency; Adrenal Crisis; 
Glucocorticoid.  
Introduction 
Addison’s disease or primary adrenal insufficiency (PAI) is a rare disorder that affects 
approximately 100/million in the population (1,2).  In Western countries, PAI is largely due 
to autoimmune adrenalitis, a condition that is more common in females and may be 
associated with other autoimmune endocrine disorders as part of the autoimmune 
polyglandular syndromes (APS 1,2) (1,2).  Patients with PAI need lifelong glucocorticoid 
replacement therapy and the majority also need mineralocorticoid replacement.  Despite 
modern approaches to management, patients are at increased risk of morbidity and mortality, 
some of which is attributable to adrenal crises (AC) (3-7).  These acute episodes of severe AI, 
which occur during periods of physiological stress, have an estimated mortality rate of 
0.5/100 PY (8).    
 As ACs are infrequent emergency presentations, there may be uncertainty around the 
diagnosis, and misclassifications of symptomatic AI as ACs and vice versa can occur (9).  
Adrenal crises can be defined as episodes of acute AI with hypotension that may be 
associated with electrolyte abnormalities (hyponatraemia, hyperkalaemia); alterations in 
consciousness; and acute abdominal symptoms, that rapidly improve after administration of 
intravenous hydrocortisone (9).  ACs occur at a rate of approximately 5-8/100 patient years in 
treated PAI, may vary in incidence between patient subgroups, and appear to be increasing in 
frequency (8-12).  Comorbidities, particularly Type 1 diabetes mellitus (T1DM) are thought 
to increase the risk of an AC (9,12).  In patients with comorbid T1DM, this increase may be 
due to difficulties managing the requirements of both conditions during an intercurrent illness 
(9,12). 
 All patients with AI should be educated to increase their glucocorticoid replacement, 
“stress dose”, during an episode of physiological stress, most commonly an acute infection-
related illness.  Patients are advised to double or triple their oral glucocorticoid dose in these 
situations but, when this cannot be taken or absorbed, for example when there is diarrhoea or 
vomiting, or when symptoms are severe or evolving rapidly, patients are advised to 
administer an intramuscular (IM) [or subcutaneous (SC)]  injection of hydrocortisone and 
seek medical attention promptly (2,9, 13, 14, 15).  However, the persistent incidence of ACs 
in a number of populations suggests that management of AI during episodes of illness is not 
always successful, although the reasons for this are not clear.  This study aims to identify 
factors that may explain the continued occurrence of ACs in patients with treated PAI. 
Methods 
The Hunter New England area health service provides health care to a large regional area, 
with a population of nearly 1 million people in New South Wales, Australia (16).  It 
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comprises a large urban area with smaller semi-urban and some rural areas.  There is one 
main public referral hospital, another public hospital, a private hospital sector providing some 
tertiary services, and a number of smaller local hospitals providing limited services to a local 
community (16).  Data on all admissions to these hospitals are coded according to the ICD-
10-AM (17) and stored securely at each health service. 
For the purposes of this study, all patients with a diagnosis of an AC (E27.2) or PAI 
(E27.1) who had at least one admission to the referral hospital between 2000 and 2017 were 
eligible for inclusion.  Hospital staff electronically screened the database for all eligible 
patient medical record numbers, which were extracted into a dataset.  Using these, each 
electronic patient record was reviewed remotely using a password protected access code.  For 
each patient with a confirmed PAI diagnosis, the first admission and all subsequent hospital 
attendances during the study period were reviewed.  Where a presentation was due to an 
acute medical illness, the record was assessed in detail.  Each patient was allocated a unique 
study number and each attendance was given an episode number linked to the study number.  
The following variables were extracted from each eligible presentation: age, sex, principal 
diagnosis, comorbid diagnoses, any procedures, whether the patient had used stress dosing 
and the type of stress dose, electrolytes, blood pressure on presentation, symptoms of AI, AC 
diagnosis, diabetic ketoacidosis (DKA), whether the patient was admitted, length of stay 
(LOS) and whether the patient was alive at discharge.  Data on each patient was deidentified 
and entered into an Excel (Microsoft Excel Version 16.24) database.   
For this analysis, only those patients who were receiving treatment for PAI were selected 
and episodes of hospital attendance prior to, or for, the initial diagnosis of PAI were 
excluded. 
Data Management 
Patient age was analysed as both a continuous variable and according to 10 year age groups.  
The number of presentations, admissions, episodes of treatment in which stress dosing had 
been reported were coded manually for each patient.  For other variables, the following 
definitions were used: hyperkalaemia: serum potassium greater than 5.0 mmol/l; 
hyponatraemia: serum sodium less than 135 mmol/l; hypoglycaemia: glucose less than 3.5 
mmol/l; and hyperglycaemia: glucose greater than 7.0 mmol/l.  Hypotension was classified as 
a systolic blood pressure (sBP) of 100mg Hg or below.  An AC was considered present when 
this was recorded in the medical record by the treating clinician (Clin-AC).  However, given 
the possibility of AC misclassification, ACs with hypotension were further classified as 
clinician-diagnosed AC with hypotension (Clin-AC-hypo).  Patients with hypotension which 
did not have a recognisable non-PAI cause were also identified (hypo-non-Clin-AC).  These 
two groups of patients were recategorized into a “true AC” group and were compared to the 
remaining patients, who were considered to have “symptomatic AI”. 
Statistical analysis  
The data were analysed using the SPSS software package version (SPSS Statistics Version 
25).   Differences in continuous variables between groups were assessed using t-tests and, 
where the variances were unequal, appropriate significance tests were used.  Categorical 
variables were evaluated using Chi sq or Fishers exact tests.  A logistic regression model was 
developed to assess the relationship between demographic and illness-related variables on the 
use of stress dosing in the study sample.  Wald Chi sq statistics were used to assess the 
significance of each variable in the model.  
The study was approved by the St Vincent’s Hospital, Sydney HREC, the Hunter New 
England Health Service HREC, and the HREC of the University of Notre Dame, Australia. 
Results 
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Patients 
During the period 2000 to 2017, there were 252 attendances by 56 patients with PAI, who 
were on glucocorticoid replacement therapy, and who had at least one admission to the study 
hospital for an acute illness.  This equates to an approximate incidence of one attendance per 
patient every three years.  Of these 49 (87.5%) patients had non-T1DM PAI and 7 (12.5%) 
had both PAI and T1DM.  Comorbid thyroid disease was present in 52.0% (n=131) of the 
attendees (Table 1).  Women comprised 60.7% (n=34) of the patients.  Two thirds (66.1%, 
n=37) of the patients were found to have never used any kind of stress dosing prior to any 
attendance at the study hospital.  Of those patients who had stress dosed, 11 (19.6%) had one 
recorded attempt at dose escalation, 5 (8.9%) had a record of dose escalation at 2 
presentations; and there was 1 patient (1.8%) for each of 3, 6 and 16 separate presentations in 
which there was stress dosing before arrival.   
Attendances at hospital 
The majority (83.7%, n= 211) of the 252 attendances resulted in an admission (Table 1).  
Females comprised two thirds (174 (69.0%)) of the of attendees.  The mean age of patients 
was 53.7 (19.6) years and 29.0% (n=73) were aged 70 or more years.  The median LOS was 2 
(IQR 1-5) days and 99 (39.3%) admissions were for one day only.  Nearly three quarters 
(73.4%, n=185) of the patients were treated with IV hydrocortisone (Table 1). 
Any form of dose escalation was used by 17.9% (n=45) of the patients prior to 
attendance.  Oral stress dosing was used before 40 presentations (15.9%) and in 7 (2.8%) 
there was a record of prior IM hydrocortisone administration (one of these was administered 
by a family doctor).  There was no record of SC hydrocortisone administration.  Nearly half 
(48.4%, n=182) the attendees arrived by ambulance.   
Deaths in hospital 
There were 5 (2.0%) in-hospital deaths but in only 1 had an AC been diagnosed but 4 had 
been administered IV hydrocortisone.  Of the 5 deaths, 3 were patients who had PAI only and 
2 had comorbid PAI/T1DM. Of the PAI-only patients, none attempted stress-dosing, none 
had an AC recorded and all 3 received IV HC. Causes of death were complex and due to 
extensive comorbid disease. The first was due to a fractured neck of femur leading to 
cardiorespiratory failure. The second had many diagnoses listed as contributing to the cause 
of death including: hepatic encephalopathy, liver failure, aspiration pneumonia, small bowel 
obstruction and sepsis. The third was due to multi-system failure (hepatic, renal, respiratory) 
as a result of sepsis. Of the 2 deaths from PAI/T1DM patients, none attempted stress-dosing, 
one patient had an AC recorded and received IV HC, the other did not receive IV HC. Causes 
of death were listed as sepsis from a pressure sore and cerebral anoxia. 
Adrenal Crisis Diagnoses and Hypotension 
In 63 (25.0%) of the presentations a clinician diagnosed AC (Clin-AC) was recorded, and in 
21 (33.3%) of these, stress dosing had been used prior to attendance.  Almost all (93.7%, 
n=59) patients with Clin-AC were given IV hydrocortisone (Table 1).  Nearly half (47.6%, 
n=30) of these patients had hypotension (Clin-AC-hypo) and the remainder (n=33, 52.4%) 
were normotensive.  There were 26 (10.3%) patients who were not diagnosed with an AC but 
who, on arrival, had hypotension which appeared attributable to PAI (hypo-non-Clin-AC).  
These patients were combined with the clin-AC-hypo group as the “true AC” category of 
presentations (n=56, 22.2% of all attendances).   
Among the patients in the “true AC” category, 31 (55.4%) had hyponatraemia; 13 
(23.2%) had hyperkalaemia; 3 (5.4%) had hypoglycaemia; 9 (16.1%) had reduced 
consciousness; 15 (26.8%) had used any form of stress dosing; 12 (21.4%) had been stress 
dosed orally; and 5 (8.9%) had used IM hydrocortisone.  Patients in this group were 
significantly younger than the remaining patients (43.5 (18.3) and 56.6 (19.0) years 
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respectively, p<0.001).  Patients in the “true AC group” also had a significantly higher 
burden of vomiting than the remaining patients (n=40 (71.4%) and n=80 (40.8%) 
respectively, p<0.001).   Infection (n=32 (57.1%) was more common in the “true AC” group 
than in those with symptomatic AI (n=82, 41.8%) (p<0.05) as was a diagnosis of 
gastroenteritis (n=14 (25.0%) and n=17 (8.7%) respectively, p<0.01). 
 Vomiting and Diarrhoea 
There were 120 (47.6%) presentations in which the patient had vomiting but in only 33 
(27.5%) of these had the patient used any form of dose escalation and, in only 5 cases, was 
IM hydrocortisone used.  Diarrhoea was less frequently reported, affecting 53 (21.0%) 
attendees.  Of these, only 5 (9.4%) used any form of stress dosing - 2 used IM and 3 used oral 
stress dosing.  Most of the patients (90.6%, n=48) who had diarrhoea also had vomiting.   
Almost all (95%, n=114) patients who had vomiting were given IV hydrocortisone, as were 
all patients with diarrhoea.  Of those who reported vomiting, 35.8% (n=43) were classified as 
having a clin-AC and 40.8% (n=49) were hypotensive on admission.    
Comorbid Disease 
The 7 patients with T1DM and PAI contributed 37 presentations to the study hospital.  
Among these attendances were 7 (18.9%) in which a Clin-AC was recorded and in one 
quarter (27.0%, n=10) of all the attendances the patient was hypotensive on arrival (Table 2)  
After reclassification, 9 (24.3%) of the T1DM patients were considered to have had a “true 
AC”.  Nearly two thirds (64.9%, n=24) had hyperglycaemia; 18.9%, (n=7) had 
hypoglycaemia, both of which were significantly higher than those found in non-T1DM PAI 
patients (Table 2).  DKA was diagnosed in 11 (29.7%) presentations.   Patients with both 
T1DM and PAI had no record of IM hydrocortisone use, and only 5 (13.5%) had used oral 
glucocorticoid dose escalation prior to attendance at hospital; in 1 presentation the patient had 
increased their insulin and 2 had increased their glucose, with another 5 patients being given 
glucose in the ambulance. 
Comorbid cardiovascular disease was more prevalent in older patients (mean age (sd) 
with CVD: 71.0 (10.5) years and without: 50.4 (19.2) years, p<0.0001), as was T2DM (mean 
age with T2DM: 63.6 (48.9) years and without: 48.9 (21.0) years, p<.0001) and thyroid 
disease (mean age with thyroid disease: 61.4 (17.5) and without: 45.3 (18.2) years, 
p<0.0001).  In addition, among older patients, the acute symptoms of confusion (mean age 
(sd) with confusion: 72.1 (14.2) and without: 52.4 (19.3) years, p<0.0001) and reduced 
consciousness (mean age (sd) with reduced consciousness: 63.9 (16.4) and without: 51.8 
(19.6), p<0.0001) were more common.  By comparison, patients who were hypotensive were 
significantly younger than normotensive patients (47.5 (19.9) and 56.4 (18.8) years 
respectively, p<0.01).   Similarly, patients who had vomiting were younger than patients who 
did not (46.8 (18.7) years and 59.9 (18.2) years respectively, p<0.0001), as were patients who 
had abdominal pain on presentation (with pain: mean age (sd) 50.0 (19.7) years and without 
55.9 (19.2) years, p<0.05).  In addition, patients who had used any form of stress dosing were 
younger than those who had not (41.2 (21.0) years and 56.4 (18.2) years respectively, 
p<0.0001).  The age distribution of patients with Clin-AC, hypotension and who had used 
stress dosing is shown in Figure 1. 
Predictors of Stress Dosing 
Logistic regression modelling was used to predict which demographic or disease-related 
factors were associated with the use of stress dosing in this population.  Logistic models 
showed that three factors were independent predictors of the use of dose escalation.  These 
were patient age: OR 0.96 (0.94, 0.98), for each year of increasing age; vomiting: OR=2.76 
(1.28,5.98); and the number of presentations: OR=1.05 (1.01,1.09) for each extra 
presentation.   
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Discussion 
This comprehensive study of all presentations by patients with PAI to a referral hospital in a 
large regional area demonstrated that pre-emergent domiciliary management of AI by stress 
dosing was attempted by only a minority (33.9%) of patients and, that among those who used 
dose escalation, the recommended strategies were used inconsistently across the illness 
episodes.  When all attendances at hospital by these patients were considered, oral stress 
dosing was used in fewer than one in five presentations and in only 2.8% of the total 
attendances did a patient use IM hydrocortisone prior to arrival.  Nearly one quarter of the 
presentations included a clinician diagnosis of an AC.  Patient age was strongly associated 
with stress dosing attempts, which were made more frequently by younger rather than older 
patients.  Use of dose escalation was more likely to have occurred with an increasing number 
of prior presentations to hospital. 
 A high proportion of presentations (25.0%) were associated with a clinician-derived 
AC diagnosis and, although there appeared to be some misclassification of the syndrome of 
symptomatic AI as an actual AC among these, the proportion of presentations that included 
symptoms indicative of acute AI/AC was considerable.  Half the patients diagnosed with an 
AC by their treating clinician had hypotension (sBP <100mmHg), suggesting that there may 
still be confusion about the diagnostic criteria that are used to define an AC (9,15) and 
highlighting the value and importance of ongoing education about AI and its management 
(18).  When the presenting features were reviewed and patients were reclassified based on the 
presence of hypotension, there were 56 patients (18.8%) who were considered to have 
experienced an actual AC.  Hypotension was more common in younger patients; 
hyponatraemia was diagnosed in 39.3% and hyperkalaemia in 14.7%.  Both absolute (sBP 
less than 100mmHg) and relative (> 20mmHG lower than usual sBP) are considered 
indicative of an AC but, in this analysis, we were unable to assess relative hypotension (9).  
This may have affected the estimation of hypotension in older patients especially, given the 
elevation in blood pressure with increasing age.   
 Infection has been shown to be a major cause of AC episodes in a number of studies 
and was found to be associated with 45.2% of attendances in this population (8,19). Vomiting 
and diarrhoea are particularly hazardous in AI because patients may not absorb either their 
usual glucocorticoid replacement or any oral stress doses and, thus, are at increased risk of an 
AC.  In these situations, IM or even SC use of hydrocortisone is recommended (9,13,14).  
However, in this population, self-management strategies were either not executed at all or 
implemented in a way that would be potentially ineffective.  This is consistent with the levels 
of preparedness reported in other populations (20, 21), but is in contrast to the higher use of 
IM hydrocortisone by children with congenital adrenal hyperplasia attending the paediatric 
hospital on the same campus for treatment of an acute illness (22).  In the present study, 
among patients who were vomiting, only a minority (27.5%) reported some form of stress 
dosing and, among those who did, only 5 used IM hydrocortisone.  Hypotension on arrival to 
hospital was found in 40.8% of patients with vomiting in this study, highlighting the risks 
posed by non-absorption of oral glucocorticoids and illustrating the importance of parenteral 
glucocorticoid administration when there is vomiting and/or diarrhoea (9,15).   
 Younger patients were found to be more likely to have some of the acute symptoms of 
an AC (vomiting, abdominal pain and hypotension) than older patients in this study.  In 
addition, they were found to be more likely to use oral stress dosing strategies than the older 
patients, although these were likely to be ineffective or only partially effective because of the 
higher incidence of acute gastrointestinal symptoms in the younger patients.  By comparison, 
older patients had a greater burden of chronic comorbid disease such as cardiovascular 
disease and T2DM and were more likely to present with confusion or reduced consciousness.  
While ACs were diagnosed in all age groups and stress dosing was underused, the underlying 
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causes may differ between the age groups and, therefore, any interventions to reduce AC risk 
may need to be tailored accordingly (9, 23).  In younger people, particularly those who have 
been managed in paediatric settings, factors such as missing medications and medical 
appointments and poor adherence to prevention strategies may contribute, especially during 
the transition from paediatric to adult care arrangements (9,24,25,26).  In contrast, among 
older patients, higher levels of comorbid conditions, social isolation and cognitive issues may 
make preventive strategies more difficult to implement (21,23).   
 Those patients with PAI and comorbid T1DM had a comparable proportion of 
admissions with “true AC” diagnoses (24.3%) to patients with PAI only but there were also 
11 (29.7%) patients with T1DM who had a diagnosis of DKA, meaning that half of these 
patients attended hospital with an acute metabolic disorder.  Hypoglycaemia was also 
identified in 18.9% of the T1DM patients on arrival at hospital.  Patients with combined 
disease have been found to be at increased risk of AC events (12) which may be due to the 
complexities of managing the demands of both disorders, especially during an acute illness.  
The patients in this study with combined disease were no more likely to use oral 
glucocorticoid dose escalation than patients with PAI alone and none used IM 
hydrocortisone.  In addition, only 1 patient had increased their insulin dose and 2 had given 
themselves glucose, highlighting the need for improved self-management in patients with 
combined disease.     
 While the results from this study represent an evaluation of the illness experience of 
all patients attending the regional referral hospital, they are likely to represent an 
underestimate of the true range of PAI-related morbidity in this population, as some patients 
may have had other episodes treated elsewhere and others may have managed their AI at 
home without the need for hospitalisation.  In addition, given that the patients in this study 
were drawn from one large regional area, the generalisability of these results to other 
populations is uncertain.  ACs in this analysis were those identified and diagnosed as such by 
the treating clinician and may be affected by misclassification bias.  To address this, the 
incidence of AC was also assessed based on the presence of hypotension without an obvious 
non-AI cause.  Further, although the records were assessed thoroughly, there may have been 
episodes of stress dosing that were unreported or undocumented, resulting in an 
underestimate of the true rate of dose escalation in this population.   
 The reason for the disappointing levels of stress dose utilisation in this sample of 
patients could not be identified definitively in this analysis.  While there were no formal 
educational programs for AI patients in this area over the period of the study, each patient 
had access to medical practitioners and specialist endocrinologists, although the extent to 
which patients accessed routine medical care could not be determined.  Treatment guidelines 
for both PAI and T1DM are published, with AI recommendations including the provision of 
education on oral stress dosing and IM injection of hydrocortisone by the patient and/or their 
carer, and the use of medical identification jewellery and a steroid identification card.  
However, it has been shown in Australia and elsewhere that these are not used by all patients 
(21,25,27,28).  In this study, a positive effect of cumulative previous presentations to hospital 
on the use of stress dosing was identified.  This phenomenon has been found previously and 
indicates that there may be an experiential component to the development of stress dosing 
expertise among patients with AI (22). 
In conclusion, the results of this study demonstrate clear shortfalls in the patient-initiated 
management of AI during acute illness in patients living in a large regional area with a 
comprehensive endocrine service.  Adrenal crises are considered to be a cause of anxiety for 
many patients with AI, but in this population, it was found that a substantial number of 
patients appeared not to use any form of dose escalation and a proportion of those who did 
use oral stress dosing would have benefited from self-administered parenteral hydrocortisone.  
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Increased efforts directed at understanding the barriers to the effective implementation of AC 
prevention strategies by different sub-groups of patients may reduce the incidence of ACs.   
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Figure 1. Adrenal Crisis, Hypotension and Stress Dose Usage among Hospital Attendees with 
PAI to a Regional Hospital, NSW 2000-2017. 
Table 1. Demographic and Disease Characteristics of Hospital Attendances for Patients with 
PAI to a Regional Hospital, NSW 2000-2017. 
 Total N (%) PAI only N (%) PAI & T1DM N (%) P val 
Total Presentations 252 215 (85.3) 37 (14.7)  
Sex     
Female 174 (69.0) 148 (68.8) 26 (70.3)  
Male 78 (31.0) 67 (31.2) 11 (29.7) NS 
Age Group     
18-29 41 (16.3) 35 (16.3) 6 (16.2)  
30-39 29 (11.5) 22 (10.2) 7 (18.9)  
40-49 36 (14.3) 35 (16.3) 1 (2.7)  
50-59 25 (9.9) 21 (9.8) 4 (10.8)  
60-69 48 (19.0) 39 (18.1) 9 (24.3)  
70+ 73 (29.0) 63 (29.3) 10 (27.0) NS 
Ambulance 122 (48.4) 94 (43.7) 28 (75.7) <0.001 
AC recorded 63 (25.0) 56 (26.0) 7 (18.9) NS 
Admissions 211 (83.7) 181 (84.2) 30 (81.1) NS 
Principal Diagnosis     
Infection 114 (45.2) 103 (47.9) 11 (29.7) <0.05 
Trauma 19 (7.5) 14 (6.5) 5 (13.5) <0.05 
AI 86 (34.1) 80 (37.2) 6 (16.2) <0.05 
Gastroenteritis 31 (12.3) 31 (14.4) 0 (0.0) <0.05 
Comorbid Conditions     
Asthma/COPD 36 (14.3) 32 (17.5) 4 (12.1) NS 
Cardiovascular Disease 40 (15.9) 38 (21.5) 2 (5.7) <0.05 
Thyroid 131 (52.0) 104 (48.4) 27 (73.0) <0.01 
T2DM 82 (32.5) 82 (38.1) 0 (0.0) <0.001 
Management     
PO stress dosing 40 (15.9) 35 (16.3) 5 (13.5) NS 
IM stress dosing 7 (2.8) 7 (3.3) 0 (0.0) NS 
Any stress dosing 45 (17.9) 40 (18.6) 5 (13.5) NS 
IV Hydrocortisone 185 (73.4) 162 (75.3) 23 (62.2) NS 
Surgical intervention 14 (5.6) 9 (4.2) 5 (13.5) <0.05 
DKA recorded 11 (4.4) 0 (0.0) 11 (29.7) <0.001 
Mortality 5 (2.0) 3 (1.4) 2 (5.4) NS 
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Table 2. Signs, Symptoms and Biochemistry of Hospital Attendances for Patients with PAI to 
a Regional Hospital, NSW 2000-2017. 
 Total N (%) PAI only N (%) PAI & T1DM N (%) P val 
Signs and Symptoms     
Hypotension 77 (30.6) 67 (31.2) 10 (27.0) NS 
Fever 60 (23.8) 50 (23.3) 10 (27.0) NS 
Vomiting 120 (47.6) 105 (48.8) 15 (40.5) NS 
Diarrhoea 53 (21.0) 51 (23.7) 2 (5.4) <0.05 
Abdominal pain 96 (38.1) 86 (40.0) 10 (10.4) NS 
Reduced level of consciousness 39 (15.5) 29 (13.5) 10 (27.0) <0.05 
Confusion 16 (6.3) 15 (7.0) 1 (2.7) NS 
Lethargy 132 (52.4) 118 (54.9) 14 (37.8) NS 
Dehydration 94 (37.3) 82 (38.1) 12 (32.4) NS 
Biochemistry     
Hypoglycaemia 23 (9.1) 9 (4.2) 14 (37.8) <0.001 
Hyperglycaemia 88 (34.9) 64 (29.8) 24 (64.9) <0.001 
Hyponatraemia 99 (39.3) 85 (39.5) 14 (37.8) NS 
Hyperkalaemia 37 (14.7) 28 (13.0) 9 (24.3) NS 
Acidosis 39 (15.5) 26 (12.1) 13 (35.1) <0.001 
 
AD
VA
N
CE
 A
RT
IC
LE
:
JO
UR
NA
L 
O
F 
TH
E 
EN
D
O
CR
IN
E 
SO
CI
ET
Y
JE
S
D
ow
nloaded from
 https://academ
ic.oup.com
/jes/advance-article-abstract/doi/10.1210/js.2019-00263/5569850 by guest on 17 Septem
ber 2019
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
NC
E 
AR
TI
CL
E
AD
VA
N
CE
 A
RT
IC
LE
:
JO
UR
NA
L 
O
F 
TH
E 
EN
D
O
CR
IN
E 
SO
CI
ET
Y
JE
S
D
ow
nloaded from
 https://academ
ic.oup.com
/jes/advance-article-abstract/doi/10.1210/js.2019-00263/5569850 by guest on 17 Septem
ber 2019
